Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
7,515
datasets available to search
ShareScore release 0.7.1
Dataset results
7,515 results for “screenings”
Screen Cast / Videopräsentation: 3. digitale Coffee Lecture Forschungsdatenmanagement Sommersemester 2020, Stiftung Universität Hildesheim: Aufbereiten und Veröffentlichen.
<p>Veröffentlichte Daten bringen sehr großen Nutzen. Nur so kann, z.B. die globale, interdisziplinäre Forschung über Pandemien ermöglicht und daraus neue Erkenntnisse gewonnen werden. Das FDM soll uns die Arbeit erleichtern. Wir versuchen unser Bestes, um es so einfach wie möglich zu machen. Dafür geben wir Ihnen den Zugang zu Tools und Informationen, damit Sie Ihre Forschungsdaten besser organisieren. Häufig ist es so, dass Daten nur von einem Forscher, einer Forscherin oder einer Arbeitsgruppe bearbeitet und analysiert werden und danach auf einem USB-Stick gespeichert in einer Schublade verschwinden. Unter anderem beschäftigen wir uns mit FDM wegen einer neuartigen Datennutzung, Nachnutzung / Publikation. Ein häufiger Ansatz generischer Infrastruktureinrichtungen ist immer noch, dass Bibliotheken und RZ auf klassische Publikationsparadigma fokussieren und dabei oft den Forschungsprozess ignorieren. Wichtige Fragen sind für mich / uns wie wir Forschungsdaten übernehmen können? Und gerade: wie können wir Forschungsdaten mit den vorhandenen Recherchetools bereitstellen?</p> <p>Das Teilen von Daten ermöglicht eine weltweite Arbeitsaufteilung. Forscherinnen und Forscher können je nach Zeit, Ressourcen und Aufgabengebieten ihren eigenen Blick auf die Daten werfen und sie entsprechend ihrer individuellen Bedürfnisse analysieren.</p>
Artificial Intelligence (AI), in the Breast Cancer Screening Programme Questionnaire and Data
<p>The goal of this study is to gain insight into the level of trust of women in the Netherlands, in the decisions made by radiologists with the support of different applications of Artificial Intelligence (AI), in the Breast Cancer Screening Programme. Gaining insight into your level of trust in the decisions made by radiologists and AI regarding whether you have breast cancer or not, is of high importance, as this will help to anticipate which steps can be taken by hospitals and software developers, in the near future. The survey consists of 10 introductory questions and 42 statements and takes approximately 10 minutes to complete.</p> <p> </p>
Screen Cast / Videopräsentation: 4. digitale Coffee Lecture Forschungsdatenmanagement Sommersemester 2020, Stiftung Universität Hildesheim: Vorstellung von Muster-Einwilligungen.
<p>Es liegen Informationsblätter vor, die zeitnah auf unserer Universitätswebseite über ein Formularcenter zum 'Download' bereitgestellt werden sollen. Seit Januar 2020 liegen diese Informationen im Justiziariat. Forscherinnen und Forscher verlangen nach Muster-Einwilligungen und so entstand die Idee zum Thema Muster-Einwilligungen eine Coffee Lecture durchzuführen. Gerne wäre mitgeteilt worden, wo universitätsintern solche Formulare heruntergeladen werden können, aber es kann inzwischen gut auf externe Seiten verweisen werden, z.B. auf den Verbund Forschungsdaten Bildung. In meinem Alltag im FDM werde ich oft zum Datenschutz gefragt, z.B. wie lange die Forschungsdaten archiviert werden dürfen und ob die Daten während der Archivierung anonymisiert werden müssen.</p> <p>Forscherinnen und Forscher möchten und müssen wissen, was alles ganz genau vor der Datenerhebung beachtet werden muss.</p>
HADDOCK screening against the COVID-19 RNA dependent RNA polymerase (RdRp)
<p>The novel coronavirus (SARS-CoV-2) that has emerged from Wuhan, China in December 2019 has spread to almost all countries in the world causing a dramatic number of deaths. The current absence of antiviral treatment against the SARS-CoV-2 urges the scientific community to accelerate the drug discovery research process.</p> <p>One way to identify potential treatments and to be able to administer it swiftly is to focus on drug repurposing studies, i.e. to investigate the SARS-CoV-2 antiviral potential of drugs that have already been approved for human use.</p> <p>Proteins that are crucial for the survival and replication of the virus are the most attractive targets for such studies. Here we have focused on the SARS-CoV-2 RNA dependent RNA polymerase (RdRp) that plays an essential role in the virus replication process by screening ~2000 approved drugs (and 6 experimental ones) against this particular protein.</p> <p>This is one part of a multi-target screen emphasising the main protease (Mrpo), the RNA-dependent-RNA-polymerase (RdRp) and human ACE2. The other datasets can found at the following locations:</p> <ul> <li><a href="https://zenodo.org/record/3929438">Mpro: Shape-based assay</a></li> <li><a href="https://zenodo.org/record/3929446">Mpro: Pharmacophore-based assay</a></li> <li><a href="https://zenodo.org/record/3929463">ACE2</a></li> </ul> <p>More information about this screen along with interactive visualisations of the top compounds can be found on our website <a href="https://bonvinlab.org/covid/">bonvinlab.org</a>.</p>
HADDOCK screening against human Angiotensin Converting Enzyme 2 (ACE2)
<p>The novel coronavirus (SARS-CoV-2) that has emerged from Wuhan, China in December 2019 has spread to almost all countries in the world causing a dramatic number of deaths. The current absence of antiviral treatment against the SARS-CoV-2 urges the scientific community to accelerate the drug discovery research process.</p> <p>One way to identify potential treatments and to be able to administer it swiftly is to focus on drug repurposing studies, i.e. to investigate the SARS-CoV-2 antiviral potential of drugs that have already been approved for human use.</p> <p>Proteins that are crucial for the survival and replication of the virus are the most attractive targets for such studies. Here we have focused on the Angiotensin Converting Enzyme 2 receptor (ACE2) that acts as one of the main gateways for viral entry in the host cell. We have screened ~2000 compounds against the inhibitor-bound closed form of the receptor.</p> <p>This is one part of a multi-target screen emphasising the main protease (Mrpo), the RNA-dependent-RNA-polymerase (RdRp) and human ACE2. The other datasets can found at the following locations:</p> <ul> <li><a href="https://zenodo.org/record/3929438">Mpro: Shape-based assay</a></li> <li><a href="https://zenodo.org/record/3929446">Mpro: Pharmacophore-based assay</a></li> <li><a href="https://zenodo.org/record/3929449">RdRp</a></li> </ul> <p>More information about this screen along with interactive visualisations of the top compounds can be found on our website <a href="https://bonvinlab.org/covid/">bonvinlab.org</a>.</p>
HADDOCK pharmacophore-based screening against the COVID-19 main protease (Mpro)
<p>The novel coronavirus (SARS-CoV-2) that has emerged from Wuhan, China in December 2019 has spread to almost all countries in the world causing a dramatic number of deaths. The current absence of antiviral treatment against the SARS-CoV-2 urges the scientific community to accelerate the drug discovery research process.</p> <p>One way to identify potential treatments and to be able to administer it swiftly is to focus on drug repurposing studies, i.e. to investigate the SARS-CoV-2 antiviral potential of drugs that have already been approved for human use.</p> <p>Proteins that are crucial for the survival and replication of the virus are the most attractive targets for such studies. Here we have focused on the SARS-CoV-2 main protease (3CLpro) that plays an essential role in the virus replication process by screening ~2000 approved drugs (and 6 experimental ones) against this particular protein using a pharmacophore-based assay.</p> <p>This is one part of a multi-target screen emphasising the main protease (Mrpo), the RNA-dependent-RNA-polymerase (RdRp) and human ACE2. The other datasets can found at the following locations:</p> <ul> <li><a href="https://zenodo.org/record/3929438">Mpro: Shape-based assay</a></li> <li><a href="https://zenodo.org/record/3929463">ACE2</a></li> <li><a href="https://zenodo.org/record/3929449">RdRp</a></li> </ul> <p>More information about this screen along with interactive visualisations of the top compounds can be found on our website <a href="https://bonvinlab.org/covid/">bonvinlab.org</a>.</p>
HADDOCK shape-based screening against the COVID-19 main protease (Mpro)
<p>The novel coronavirus (SARS-CoV-2) that has emerged from Wuhan, China in December 2019 has spread to almost all countries in the world causing a dramatic number of deaths. The current absence of antiviral treatment against the SARS-CoV-2 urges the scientific community to accelerate the drug discovery research process.</p> <p>One way to identify potential treatments and to be able to administer it swiftly is to focus on drug repurposing studies, i.e. to investigate the SARS-CoV-2 antiviral potential of drugs that have already been approved for human use.</p> <p>Proteins that are crucial for the survival and replication of the virus are the most attractive targets for such studies. Here we have focused on the SARS-CoV-2 main protease (3CLpro) that plays an essential role in the virus replication process by screening ~2000 approved drugs (and 6 experimental ones) against this particular protein using a shape-based assay.</p> <p>This is one part of a multi-target screen emphasising the main protease (Mrpo), the RNA-dependent-RNA-polymerase (RdRp) and human ACE2. The other datasets can found at the following locations:</p> <ul> <li><a href="https://zenodo.org/record/3929446">Mpro: Pharmacophore-based assay</a></li> <li><a href="https://zenodo.org/record/3929463">ACE2</a></li> <li><a href="https://zenodo.org/record/3929449">RdRp</a></li> </ul> <p>More information about this screen along with interactive visualisations of the top compounds can be found on our website <a href="https://bonvinlab.org/covid/">bonvinlab.org</a>.</p>
Next-generation sequencing of newborn screening genes: The accuracy of short-read mapping
<p>We examine the effect of high homology genomic regions on the mapping of genes related to newborn screening while taking different read lengths and patient's ethnic background into consideration.</p>
Dataset for: Image-based screen capturing misfolding status of Niemann-Pick type C1 identifies potential candidates for chaperone drugs
<p>Niemann-Pick disease type C is a rare, fatal neurodegenerative disorder characterized by massive intracellular accumulation of cholesterol. In most cases, loss-of-function mutations in NPC1 gene that encodes for a lysosomal cholesterol transporter NPC1 are responsible for the disease, and more than half of the mutations are considered to interfere with biogenesis or folding of the protein. Previously we have identified a series of oxysterol derivatives and phenanthridine-6-one derivatives as pharmacological chaperones, small molecules that rescue folding defective phenotypes of a mutated NPC1, and opened an avenue to develop chaperone therapy for Niemann-Pick disease type C. Here, we established an improved image-based screen for NPC1 chaperones and performed drug-repurposing screening to identify some azole antifungals, including itraconazole and posaconazole, and a kinase inhibitor lapatinib as probable pharmacological chaperones. Photo-crosslinking probes of the compounds allowed us to detect direct binding of itraconazole to a representative folding-defective mutant, NPC1-I1061T. Competitive photo-crosslinking experiments suggested that oxysterol-based chaperones and itraconazole share the same or nearby binding site(s), and sensitivity of the crosslinking to P691S mutation on the sterol-sensing domain supported currently proposed hypothesis that their binding sites are located near the domain. Although the azoles were less effective in reducing cholesterol accumulation than the oxysterol-derived chaperone or an HDAC inhibitor LBH-589, our findings should offer new starting points for developing better pharmacological chaperones for NPC1 through medicinal chemistry efforts.</p>
Data associated to the manuscript "Computational Screening of the Physical Properties of Water-in-Salt Electrolytes"
<p>Contains input files and data used to generate the figures of the article:</p> <p>Computational Screening of the Physical Properties of Water-in-Salt Electrolytes</p> <p>Trinidad Mendez-Morales, Zhujie Li and Mathieu Salanne,<br> *ChemRxiv*, 13012646v2, 2020</p> <p>[https://doi.org/10.26434/chemrxiv.13012646.v2](https://doi.org/10.26434/chemrxiv.13012646.v2)</p> <p>*WiS-inputs.zip* contains typical [LAMMPS](https://lammps.sandia.gov/) input files for all the systems.</p> <p>The folder *transport_coefficients* contains the computed viscosities, conductivities and diffusion coefficients for all the systems.</p> <p>The folder *radial_distribution_functions* contains all the partial radial distribution functions for all the systems. The nomenclature of the atoms of the anion is provided in the file *figureS1.pdf* and the atoms from the water molecules are labelled Ow and Hw.</p>
Large scale virtual screening for finding inhibitor against the main protease from herbal medicine for SARS-Cov2 therapy
<p>The pandemic COVID-19 caused by SARS-CoV-2 has raised global health concerns. However, there is still no targeted medicine available for treatment of this disease. It is reported that 3CLpro plays an important role for the life cycle of virus and this protein has also been proved as an effective drug target in the case of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Medicinal plantsare important resource for drug discovery. Therefore, we executed large scale virtual screening on the herbal medicine library and hoped to find a potential drug againstthe main protease. As a result, we obtained three available compounds derived from Chinese herbal medicines through the docking and binding free energy calculation.Then 100 ns molecular dynamic (MD) were employed to uncover the potential mechanisms which is helpful for further drug optimization.</p>
Performance of virtual screening against GPCR homology models: Impact of template selection and treatment of binding site plasticity
<p>Rational drug design for G protein-coupled receptors (GPCRs) is limited by the small number of available atomic resolution structures. We assessed the use of homology modeling to predict the structures of two therapeutically relevant GPCRs and strategies to improve the performance of virtual screening against modeled binding sites. Homology models of the D<sub>2</sub> dopamine (D<sub>2</sub>R) and serotonin 5-HT<sub>2A</sub> receptors (5-HT<sub>2A</sub>R) were generated based on crystal structures of 16 different GPCRs. Comparison of the homology models to D<sub>2</sub>R and 5-HT<sub>2A</sub>R crystal structures showed that accurate predictions could be obtained, but not necessarily using the most closely related template. Assessment of virtual screening performance was based on molecular docking of ligands and decoys. The results demonstrated that several templates and multiple models based on each of these must be evaluated to identify the optimal binding site structure. Models based on aminergic GPCRs displayed ligand enrichment and there was a trend toward improved virtual screening performance with increasing binding site accuracy. The best models even displayed ligand enrichment better than that of the D<sub>2</sub>R and 5-HT<sub>2A</sub>R crystal structures. Methods to consider binding site plasticity were explored to further improve predictions. Molecular docking to ensembles of structures did not outperform the best individual binding site models, but could increase the diversity of hits from virtual screens and be advantageous for GPCR targets with few known ligands. Molecular dynamics refinement resulted in moderate improvements of structural accuracy and the virtual screening performance of snapshots was either comparable to or worse than that of the raw homology models. These results provide guidelines for successful application of structure-based ligand discovery using GPCR homology models.</p>
Screen of Edo photogrammetry scan
Edo-Tokyo Museum Screen painting that depicts Edo before the Great Fire of Meireki in 1657. In addition to scenes of Edo, events such as the Kawagoe muchi-uchi and hawk-hunging and boar-hunting in the outskirts of Edo that were associated with the third shogun Tokugawa Iemitsu are portrayed. There are several theories as to the dating of the screen. This orthophoto was generated from the model so the image can be show as the screen is fully extended.  here a higher res version of the ortho photo https://ibb.co/6Rjh2F1 Source: Objaverse 1.0 / Sketchfab
Results of preliminary screening tests for all dyslexic and control participants (ACI experiment)
<p>Participants' gender, ages, handedness. Results of Raven's test, Reading test, Memory span test, ANT test, and audiogram</p>
Dataset STI screening German HIV-1 seroconverter cohort
<p>The Stata file contains the raw data of a project in the scope of the German HIV-1 seroconverter cohort, run by the Robert Koch Institute, Berlin, Germany. The data covers anonymous sociodemographic and clinical information of the patients as well as results of a serologocal screening on coinfection with hepatitis B, hepatitis C and syphilis.</p>
Development of a genus-specific antigen capture ELISA for orthopoxviruses. Target selection and optimized screening
<p><strong>Raw data for quantification of anti surface protein antibody binding to vaccinia virus.</strong></p> <p>Method description</p> <p>Immuno-negative staining and electron microscopy were performed as described elsewhere (Laue, 2010). Briefly, purified VACV<sub>NYCBOH</sub> particles were inactivated by incubation in freshly prepared 2% PFA in 0.05 M HEPES (pH 7.2), sonicated and immobilized on sample supports for transmission electron microscopy. Biotinylated pAbs were titrated on BSA coated grids, until detection with 5 nm gold nanoparticle coupled streptavidin (British Biocell, Cardiff, United Kingdom) resulted in the same mean background labelling density of ~10 particles per view field at a, 87,000-fold magnification (anti-A27: 0.7 µg/mL; anti-D8: 2 µg/mL; anti-H3: 0.9 µg/mL; anti-L1: 1.9 µg/mL). Negative staining was performed with either 0.1 or 0.5% uranyl acetate solution. For quantification, only IMV particles of the mulberry form, which were found isolated from other particles, were analyzed. Randomized sampling was done in 22 evenly distributed mesh areas with five viral particles analyzed per area. Imaging was done with a Tecnai 12 BioTwin (FEI Corp.) at 120 kV and a 1k digital CCD camera (Megaview III, Olympus Soft Imaging Solutions).</p>
PanDDA analysis of SP100 screened against selection of Maybridge Fragment Library
<p>Nulear auto-antigen SP-100 screened against a selection of the Maybridge Fragment Library by X-ray crystallography.</p>
PanDDA analysis of BRD1 screened against 3D-Fragment-Consortium Fragment Library
<p>Bromodomain BRD1 screened against the 3D Fragment Consortium Fragment Library by X-ray Crystallography.</p>
Parallel reverse genetic screening in mutant human cells using transcriptomics - Data and analyses
<p>This dataset contains data files and analysis code associated with manuscript entitled "Parallel reverse genetic screening in mutant human cells using transcriptomics".</p> <p>Data files include expression profiles for over 1800 RNA-seq samples and annotations.</p> <p>Analysis files include R scripts to generate summary figures.</p>
PanDDA analysis of JMJD2D screened against Zenobia Fragment Library - HTML Summary
<p>De-methylase JMJD2D screened against the Zenobia Fragment Library by X-ray Crystallography.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.